PRNewswire / – The year 2016 marks the strengthening of Pfizer’s oncology portfolio in Brazil with the arrival of two new medicines to the country, one for lung cancer and the other for kidney cancer, both classified as targeted therapy. By focusing on a smaller group of patients, these drugs are targeted to very specific targets, improving the chances of effective responses to treatment.
Approved in more than 80 countries Xalkori (crizotinib) is the first medicament of oral administration is indicated for the treatment of lung cancer, non-small cell (NSCLC) related to a specific genetic alteration (EML4-ALK fusion), which is an important example of the application of precision medicine for cancer treatment.
Approved by the National Health Surveillance Agency (Anvisa) in February 2016, Xalkori reached the domestic market in July. The drug acts by inhibiting an enzyme produced by the fusion of the EML4 and ALK gene, a substance that promotes proliferation of tumor cells in the lung. read more
Evotec Awarded Contract from Antibiotic Research UK to Begin Integrated Drug Discovery Collaboration
HAMBURG, Germany–(BUSINESS WIRE)–Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today a collaboration with Antibiotic Research UK (“ANTRUK”) to identify alternative means of treating infections that are resistant to currently available antibiotics. The research will focus on the discovery of Antibiotic Resistance Breakers, or “ARBs”, to be used in conjunction with known antibiotics with the aim of reversing resistance and restoring clinical utility of such antibiotics. ANTRUK, the world’s first charity tackling antimicrobial resistance, was established by a network of leading UK scientists and clinicians with the mission to educate the public about microbial resistance, promote the discovery and development of new antibiotic therapies, and support those currently living with antibiotic-resistant infections.
BIOCAD: Advanced rheumatoid arthritis medicine developed in Russia
SAINT PETERSBURG, Russia–(BUSINESS WIRE)–Biotechnological company BIOCAD has developed innovative medicine for treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and other autoimmune diseases. According to scientists forecast, the new drug candidate (BCD-121) can increase the efficacy of treatment of RA up to 20% in comparison to currently available therapy regimens. BIOCAD has invested more than 155 mln. RUB., in very early development stages of BCD-121. As for today, there is no registered drug in the world with the same mechanism of action.
PARIS–(BUSINESS WIRE)–Regulatory News:
The Board of Directors of Ipsen (Euronext: IPN; ADR: IPSEY), met on 8 July 2016, and has appointed David Meek as Chief Executive Officer, effective July 18, 2016. On this date, Marc de Garidel will assume the role of non-executive chairman and will continue to serve the Board of Directors through his deep industry expertise. In addition, Marc de Garidel will advise Mayroy, the Ipsen controlling holding company.
Panama Government to Add Elsevier’s ScienceDirect and ClinicalKey to the ABC Scientific Library Program
Deal Will Bring Access to the Latest Breakthroughs in Science and Medicine for Researchers and Clinicians in Panama‘s Health and Academic Institutions
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that Access to Scientific Literature (ABC), the Scientific Library program sponsored by Panama’sMinistry of Health and Ministry of Science and Technology, have selected Elsevier’s ScienceDirect and ClinicalKey.
With this two-year collaboration agreement, the country’s researchers and health and academic institutions will have access to content and digital resources on scientific and clinical literature. This collaboration will also increase the number of entities with access to this information, on the different areas of knowledge.
Martindale Pharma® Announces Acquisition of Viridian Pharma
Expands Hospital-Initiated Medicines Portfolio With a Focus on Neonatology and Paediatrics
Martindale Pharma, the UK-based international specialty pharma company, today announced it has completed the acquisition of Viridian Pharma, a UK-based developer and supplier of niche pharmaceutical products. Although financial terms were not disclosed, the acquisition will be immediately accretive to earnings.
This acquisition is part of Martindale Pharma’s strategy to expand its product portfolio and actively support further growth of its hospital-initiated medicines product range.
InfuSMART Roll-out Begins in Europe; Planned Across Six Countries – Netherlands, UK, Spain,Germany, Italy and France Over Next Few Months
– InfuSMART is Developed by Sun Pharma’s R&D Team in India
– Ready-to-administer Medicines are Expected to Play an Increasing Role due to Improved Safety, Convenience and Time Saving Benefits
As part of its business strategy to build a meaningful and differentiating presence in Global Oncology Therapy market, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) today announced the roll-out of Gemcitabine InfuSMART in Europe. InfuSMART is a technology in which oncology products are developed in a Ready-To-Administer (RTA) bag. Until now, compounding of oncology products was done at compounding centres or compounded in hospital pharmacies, an extra step before the medicine can be administered to patients. With the roll-out of Gemcitabine InfuSMART, Sun Pharma becomes world’s first pharmaceutical company to manufacture and launch a licensed RTA oncology product. This innovatively differentiated product will have a shelf life of two years. Over the next few months, Sun Pharma will launch Gemcitabine InfuSMART across Netherlands, UK, Spain, Germany, Italy & France.
Galderma Announces FDA Approval of Full Prescription-Strength Differin® Gel For Over-the-Counter Acne Use
PRNewswire/ — Galderma, a global leader focused on medical solutions in skin health, today announced that its U.S. affiliate, Galderma Laboratories, L.P. received approval from the U.S. Food and Drug Administration (FDA) for Differin® Gel (adapalene gel 0.1%) as an over-the-counter (OTC) treatment for acne. This approval makes Differin® Gel the first and only OTC acne product containing a full prescription-strength retinoid. It also marks the first new, FDA-approved active ingredient to be introduced to the OTC acne category in over three decades.